Q: do you folks have any info on ocgn ? thanks
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Thoughts on latest earnings and hold,add to,or sell and explanation please. Thanx.
Q: Would appreciate your analysis of CPH's Q1 results that were released last week.
Q: I have below weight holdings in DHR and TMO and am looking to sell my holdings in one of these and use the proceeds to increase my holdings in the other. Which of these 2 do you prefer.
Thanks
Peter
Thanks
Peter
Q: What are you current thoughts on this company and its possible purchase of lifelabs?
Q: What do you think of this company and its future? Is it a buy hold or sell.
Thank you
Thank you
Q: Hello ,
It appears from various questions and answers, well's fundamentals are good. If the market does not seem to like it much, in your experience, is it best to move on. Unless there is a takeover, do you see a potential of Well surging. Last report as outlined was good and it did well but now retracing.. thanks for your assistance.
It appears from various questions and answers, well's fundamentals are good. If the market does not seem to like it much, in your experience, is it best to move on. Unless there is a takeover, do you see a potential of Well surging. Last report as outlined was good and it did well but now retracing.. thanks for your assistance.
Q: Thoughts please on their latest quarter, I think I can guess :-)
Do you see any signs pointing to a turn around?
Thanks!
Do you see any signs pointing to a turn around?
Thanks!
Q: Thinking of taking a position. Seems oversold for a quality company. What are your thoughts for short and long term buys?
Q: thoughts and projecting 5 years
Q: Results were good. Market is not supporting Well. What's missing. I just don't get this one.
Q: Please comment on the recent results?
Thanks
Thanks
Q: Morning 5i,
I haven't been able to find DHT.UN results for its quarterly earnings which I think were released on May 6. Perhaps I just don't know where to look. In any event could you please provide your analysis of the results along with any general or specific commentary you might have about the name. I've done well by it and would like to continue holding unless something material has fundamentally changed, or looks like it might.
Thanks,
Peter
I haven't been able to find DHT.UN results for its quarterly earnings which I think were released on May 6. Perhaps I just don't know where to look. In any event could you please provide your analysis of the results along with any general or specific commentary you might have about the name. I've done well by it and would like to continue holding unless something material has fundamentally changed, or looks like it might.
Thanks,
Peter
Q: Your interpretation of earnings please and opinions going forward.
Thank you
Thank you
-
Illumina Inc. (ILMN $126.69)
-
Abbott Laboratories (ABT $107.15)
-
CVS Health Corporation (CVS $71.85)
-
Danaher Corporation (DHR $190.44)
-
Eli Lilly and Company (LLY $916.82)
-
Thermo Fisher Scientific Inc (TMO $469.93)
-
UnitedHealth Group Incorporated (DE) (UNH $280.34)
-
Novo Nordisk A/S (NVO $37.05)
-
State Street Health Care Select Sector SPDR ETF (XLV $146.62)
Q: Good morning;
I own the 4 stocks referenced at a 4.5% weight in my portfolio. ILMN was purchased as a turnaround candidate so I wish to keep it. XLV to hedge. UNH I have my initial investment out; it has bounced around quite a bit lately with no clear path but a target +/$75 above current price. May 1st you commented CVS is not one you would add to and it could be a value trap. I've owned it since prior to COVID and missed my opportunity to sell it off.
I want to stay exposed and grow my exposure a bit to the US (and maybe Canadian) health care sector. Other than a very occasional flare of positive results this sector has not been very beneficial to my portfolio other than a bit of modest income. I could part with (in order) CVS, UNH, XLV to build better growth exposure. I would appreciate your top 5 recommended options along with why you would put them on the list.
Thanks very much.
Dave
I own the 4 stocks referenced at a 4.5% weight in my portfolio. ILMN was purchased as a turnaround candidate so I wish to keep it. XLV to hedge. UNH I have my initial investment out; it has bounced around quite a bit lately with no clear path but a target +/$75 above current price. May 1st you commented CVS is not one you would add to and it could be a value trap. I've owned it since prior to COVID and missed my opportunity to sell it off.
I want to stay exposed and grow my exposure a bit to the US (and maybe Canadian) health care sector. Other than a very occasional flare of positive results this sector has not been very beneficial to my portfolio other than a bit of modest income. I could part with (in order) CVS, UNH, XLV to build better growth exposure. I would appreciate your top 5 recommended options along with why you would put them on the list.
Thanks very much.
Dave
Q: Hi 5i, pls provide your opinion on this mornings 1st quarter results release. The numbers and increase in forward guidance look great. Would your estimate for FY24 earnings change from .22? Estimate for FY25? Thx.
-
Eli Lilly and Company (LLY $916.82)
-
McKesson Corporation (MCK $898.79)
-
Novo Nordisk A/S (NVO $37.05)
Q: No healthcare exposure other than WELL, could you compare these, or if you have a better idea?
-
Abbott Laboratories (ABT $107.15)
-
Danaher Corporation (DHR $190.44)
-
Eli Lilly and Company (LLY $916.82)
-
Thermo Fisher Scientific Inc (TMO $469.93)
-
Novo Nordisk A/S (NVO $37.05)
-
iShares Global Healthcare ETF (IXJ $92.61)
-
State Street Health Care Select Sector SPDR ETF (XLV $146.62)
-
WELL Health Technologies Corp. (WELL $4.19)
-
iShares U.S. Healthcare ETF (IYH $61.18)
Q: Can you account for the recent drop in TMO and possibly also for its quick recovery.
Portfolio analytics call for more in my healthcare sector. Do you prefer ETFs or individual companies here?
Please recommend a few of your favourite quality long-term holds for both (more American than Canadian, but both if possible).
Thanks as always.
Portfolio analytics call for more in my healthcare sector. Do you prefer ETFs or individual companies here?
Please recommend a few of your favourite quality long-term holds for both (more American than Canadian, but both if possible).
Thanks as always.
-
State Street Health Care Select Sector SPDR ETF (XLV $146.62)
-
iShares U.S. Medical Devices ETF (IHI $54.87)
Q: Hi Peter, Ryan, and Team,
We hold IHI in our non-registered investment account, and I recently looked at US News (https://money.usnews.com/investing/articles/best-health-care-etfs-to-buy-now) which stated:
“The main issue holding weight-loss drugs back is their exorbitant price tag, with Ozempic clocking in at $980 per month and Wegovy at up to $1,300 per month. If weight-loss prices fall or if insurers and employers start covering their costs for consumers, that could negatively impact medical device-oriented funds like IHI.”
Do you concur with this view? I note that XLV has surpassed IHI in four out of seven periods from one month to ten years. Alternatively, since Portfolio Analytics indicates that we need to increase Healthcare exposure, would starting a new position in XLV at this time be prudent?
Thanks in advance for your advice.
We hold IHI in our non-registered investment account, and I recently looked at US News (https://money.usnews.com/investing/articles/best-health-care-etfs-to-buy-now) which stated:
“The main issue holding weight-loss drugs back is their exorbitant price tag, with Ozempic clocking in at $980 per month and Wegovy at up to $1,300 per month. If weight-loss prices fall or if insurers and employers start covering their costs for consumers, that could negatively impact medical device-oriented funds like IHI.”
Do you concur with this view? I note that XLV has surpassed IHI in four out of seven periods from one month to ten years. Alternatively, since Portfolio Analytics indicates that we need to increase Healthcare exposure, would starting a new position in XLV at this time be prudent?
Thanks in advance for your advice.
Q: What does the market expect this week?
Thx
Thx